Larosuzet

Larosuzet integrates the strengths of ezetimibe, an intestinal cholesterol absorption inhibitor, and rosuvastatin, an HMG-CoA reductase inhibitor, to achieve optimal lipid control. This dual-action formula reduces LDL-C and total cholesterol levels more effectively than either agent alone. Larosuzet is suitable for treating hypercholesterolemia and mixed dyslipidemia, providing a balanced and efficient approach to cardiovascular risk reduction. Available in various fixed-dose combinations, including 10/10 mg, 10/20 mg, and 10/40 mg (ezetimibe/rosuvastatin)